Skip to main content
OpenTrials
Completed

NCT Number: NCT02078908

The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study

The purpose of this study is to investigate the effect of different doses of sodium nitrite infusion in 12 healthy subjects. The effects on renal handling of nitrite, nitrate, sodium and water, plasma concentrations of vasoactive hormones, peripheral (brachial) and central blood pressure will be evaluated.

Hypothesis

Sodium nitrite infusion

1. increases urinary sodium excretion and renal filtration rate 2. lowers blood pressure, central as well as peripheral 3. affects vasoactive hormones 4. it is possible to establish a dose that affects the renal function with only minor effect on the blood pressure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Department of Medical Research, Regional Hospital Holstebro

Holstebro, 7500, Denmark

About this study

Background:

Nitric oxide (NO) is an important vasodilating molecule with a very complex biochemistry and metabolism. NO is classically synthesized from L-arginin by endothelial nitric oxide synthase (eNOS) located in the endothelial cell lining. Several chronic cardiovascular diseases such as hypertension, chronic kidney disease and diabetes are accompanied by endothelial dysfunction and hence diminished synthesis of NO. NO is a very reactive molecule and direct investigation of its function are limited and it has mainly been investigated by inhibition of eNOS. Recent research has shown that sodium nitrite is readily converted to NO by enzymes in vivo. The effects of sodium nitrite on renal variables, vasoactive hormones and central blood pressure are previously unexamined. It is now possible to achieve serial estimations of the central aortic systolic pressure (CASP) by newly designed wrist born device.

Hypothesis:

  • Sodium nitrite infusion increases the urinary sodium excretion and glomerular filtration rate (GFR) in a dose related manner.
  • Sodium nitrite infusion increases plasma levels of nitrite, nitrate, NO and cyclic guanosine monophosphate (cGMP)
  • Sodium nitrite infusion lowers the peripheral and central blood pressure
  • Renal clearance of nitrite is constant and not dose dependent
  • Sodium nitrite infusion affects vasoactive hormones
  • It is possible to establish a dose that affects the renal variables with only minor effect on the blood pressure.

Purpose:

The purpose of this study is to investigate the effects of sodium nitrite infusion on

  • Renal handling of nitrite, nitrate, sodium and water
  • Plasma concentrations of vasoactive hormones
  • Peripheral (brachial) blood pressure and CASP

Design:

12 healthy subjects are recruited in this randomised, cross over, placebo controlled, single-blinded study. Each subject will attend to four examination days. Four days prior to each examination day subjects are given a standardized diet with a low level of nitrate and nitrite. On the evening before the examination day the subjects take a single dose of lithium carbonate 300 mg in order to measure lithium clearance. On the examination days subjects are receiving a two hour infusion of either placebo (isotonic sodium chloride) or one of three doses of sodium nitrite. During the four examination days each subject receives all treatments in random order.

Perspectives:

Knowledge regarding hemodynamic and renal dose-response relationship is essential, in order to carry out future planned studies of the nitrite-NO system, in hypertensive subjects and during simultaneous modulation of various enzyme systems, involved in the conversion of nitrite to NO. Increasing knowledge about the nitrite-NO system can contribute to changing the clinical practise of diagnostics and treatment of cardiovascular diseases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 18,5-30 kg/m2
  • Women must use safe contraception

Exclusion criteria

  • Tobacco smoking, medicine or substance abuse
  • Weekly consumption of more than 21 standard drinks of alcohol for men and 14 standard drinks of alcohol for women (1 danish standard drink equals 12 grams of alcohol)
  • Medical treatment in the last 2 weeks except for contraception
  • Pregnancy or nursing
  • Diabetes mellitus
  • estimated glomerular filtration rate (eGFR) < 60 ml/min
  • neoplasm
  • clinically significant heart, lung, liver, kidney, metabolic og neurologic disease
  • clinically significant findings in screening blood samples, urine sample or ECG
  • Office blood pressure > 140/90 mmHg
  • Blood donation within 1 month of the first day of investigation

Treatment and study plan

Sodium nitrite, 40 micrograms/kg/hour

Drug

Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour

Other names: NaNO2, ATC V03AB08, EV substance code: SUB15308MIG, CAS15 number: 7632-00-0

Sodium nitrite, 120 micrograms/kg/hour

Drug

Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour

Other names: NaNO2, ATC V03AB08, EV substance code: SUB15308MIG, CAS15 number: 7632-00-0

Sodium nitrite, 240 micrograms/kg/hour

Drug

Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour

Other names: NaNO2, ATC V03AB08, EV substance code: SUB15308MIG, CAS15 number: 7632-00-0

Placebo

Drug

Continuous 2 hour infusion of sodium chloride, 25 ml/hour

Other names: Sodium chloride

Primary outcomes

  1. Fractional urinary sodium excretion

    Time frame: One day

Secondary outcomes

  1. Nitrite clearance

    Time frame: One day

  2. Nitrate clearance

    Time frame: One day

  3. Glomerular filtration rate

    Time frame: One day

    Measured by determent renal clearance of 51Cr-EDTA (51-chrome ethylenediaminetetraacetic acid) using constant infusing technique

  4. Proximal sodium transport

    Time frame: One day

    Proximal sodium transport is estimated by lithium clearance

  5. Free water clearance

    Time frame: One day

  6. Urinary excretion of cyclic guanosine monophosphate (cGMP)

    Time frame: One day

  7. Urinary excretion of epithelial sodium channels (ENaC)

    Time frame: One day

  8. Urinary excretion of water channels (aquaporin-2)

    Time frame: One day

  9. Plasma concentration of renin

    Time frame: One day

  10. Plasma concentration of angiotensin 2

    Time frame: One day

  11. Plasma concentration of aldosterone

    Time frame: One day

  12. Plasma concentration of atrial natriuretic peptide (ANP)

    Time frame: One day

  13. Plasma concentration of brain natriuretic peptide (BNP)

    Time frame: One day

  14. Plasma concentration of cyclic guanosine monophosphate (cGMP)

    Time frame: One day

  15. Plasma concentration of endothelin

    Time frame: One day

  16. Plasma concentration of vasopressin (AVP, ADH)

    Time frame: One day

  17. Peripheral (brachial) blood pressure

    Time frame: One day

    Measured by oscillometric sphygmomanometer, Omron 705IT, Omron Matsusaka CO. Ltd.

  18. Central aortic systolic blood pressure (CASP)

    Time frame: One day

    Estimated by tonometric pulse wave analysis. Device: BPro from HealthSTATS International, Singapore

Sponsors and collaborators

Lead sponsor

Erling Bjerregaard Pedersen

Other

Registry information

Official study title

The Effect of Sodium Nitrite on Renal Variables, Brachial and Central Blood Pressure in Healthy Humans. A Randomized, Cross Over, Placebo Controlled Dose-response Study

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Mar 5, 2014
Registry last updated
Oct 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.